Keros Therapeutics announced the launch of a proposed underwritten public offering of $120M of shares of its common stock. Goldman Sachs, Leerink Partners, Piper Sandler and Truist Securities are acting as joint book-running managers for the offering.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KROS:
- Keros Therapeutics price target lowered by $25 at BTIG, here’s why
- Keros says signaling by KER-050 demonstrated potential to treat myelofibrosis
- Keros Therapeutics says KER-050 treatment reduced iron overload
- Keros Therapeutics presents clinical data from KER-050 program
- Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
